US Nephrologists Are Optimistic About the Potential for Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs) for the Treatment of Renal Anemia

Thursday, August 1, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

According to Spherix Global Insights, nephrologists have high expectations that this novel class of oral agents may offer a safer way to treat renal anemia compared to erythropoietin stimulating agents (ESAs) such as Amgen's Epogen and Aranesp



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store